Jennifer Cook Sells 37,167 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Jennifer Cook sold 37,167 shares of the stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $70.00, for a total value of $2,601,690.00. Following the completion of the sale, the director owned 8,383 shares in the company, valued at approximately $586,810. The trade was a 81.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

BridgeBio Pharma Trading Up 0.5%

NASDAQ:BBIO opened at $69.69 on Friday. The company has a market cap of $13.65 billion, a price-to-earnings ratio of -18.63 and a beta of 0.97. BridgeBio Pharma, Inc. has a twelve month low of $41.80 and a twelve month high of $84.94. The stock has a fifty day simple moving average of $69.03 and a 200-day simple moving average of $71.84.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.14). The firm had revenue of $194.51 million for the quarter, compared to analysts’ expectations of $178.07 million. The company’s revenue was up 66.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.88) EPS. As a group, equities research analysts predict that BridgeBio Pharma, Inc. will post -2.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on BBIO shares. Morgan Stanley raised their target price on shares of BridgeBio Pharma from $94.00 to $98.00 and gave the stock an “overweight” rating in a research report on Thursday, May 28th. William Blair initiated coverage on BridgeBio Pharma in a report on Tuesday, March 10th. They issued an “outperform” rating for the company. Truist Financial increased their price objective on BridgeBio Pharma from $95.00 to $102.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Royal Bank Of Canada started coverage on BridgeBio Pharma in a report on Thursday, April 9th. They set an “outperform” rating and a $100.00 price objective on the stock. Finally, Barclays reaffirmed an “overweight” rating on shares of BridgeBio Pharma in a research report on Tuesday, March 10th. Twenty-one equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $92.90.

Institutional Investors Weigh In On BridgeBio Pharma

Hedge funds have recently modified their holdings of the business. Commonwealth Equity Services LLC boosted its stake in shares of BridgeBio Pharma by 4.9% during the fourth quarter. Commonwealth Equity Services LLC now owns 5,179 shares of the company’s stock valued at $396,000 after purchasing an additional 244 shares in the last quarter. Farther Finance Advisors LLC raised its stake in BridgeBio Pharma by 91.4% in the fourth quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock worth $39,000 after buying an additional 245 shares in the last quarter. State of New Jersey Common Pension Fund D lifted its holdings in BridgeBio Pharma by 0.5% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 51,896 shares of the company’s stock worth $3,970,000 after buying an additional 246 shares during the period. CWM LLC lifted its holdings in BridgeBio Pharma by 4.3% during the fourth quarter. CWM LLC now owns 6,444 shares of the company’s stock worth $493,000 after buying an additional 265 shares during the period. Finally, Xponance LLC boosted its position in BridgeBio Pharma by 2.2% during the 4th quarter. Xponance LLC now owns 12,536 shares of the company’s stock valued at $959,000 after acquiring an additional 272 shares in the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.